UCB and AstraZeneca have announced a partnership to register and commercialise UCB’s PEGylated anti-TNF alpha drug Cimzia (certolizumab pegol), for the treatment of rheumatoid arthritis and Crohn’s disease in Brazil.

Cimzia has been approved by the US Food and Drug Administration for moderate to severe Crohn’s disease in adults who have not shown an adequate response to conventional therapy as well as for the treatment of rheumatoid arthritis.

AstraZeneca Brazil president and representative director Rubens Pedrosa said that AstraZeneca has been one of the fastest-growing pharma companies in the country.

“Cimzia will complement our portfolio of innovative medicines and support our continued growth in this important market,” Pedrosa said.